Global control of hepatitis B virus infection

Lancet Infectious Diseases

Volumn 2, Issue 7, 2002, Pages 395-403

  Kao, Jia Horng ^a   Chen, Ding Shinn ^a,b  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE;

DISEASE COURSE; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNIZATION; INFECTION CONTROL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; REVIEW; VACCINATION; VIRUS CELL INTERACTION; VIRUS PATHOGENESIS;

EID: 0036293243     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(02)00315-8     Document Type: Review

References (98)

1. Hepatitis B virus infection
2. Global programmeme for control of hepatitis B infection
3. From hepatitis to hepatoma: Lessons from type B viral hepatitis
4. Prevention of hepatitis B virus transmission by immunisation: An economic analysis of current recommendations
5. A "new" antigen in leukemia sera
6. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis
7. DNA polymerase associated with human hepatitis B antigen
8. DNA polymerase in the core of the human hepatitis B virus candidate
9. The genome of hepatitis B virus
10. Hepatitis B Virus Infection
11. Overview of hepatitis B and C viruses
12. Rous-Whipple Award Lecture. Viruses, immunity, and cancer: Lessons from hepatitis B
13. Immunology of hepatitis B infection
14. Genomic heterogeneity of hepatitis B virus in a 54 year old woman who contracted the infection through materno-fetal transmission
15. Typing hepatitis B virus by homology in nucleotide sequence: Comparison of surface antigen subtypes
16. Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S-gene
17. A new genotype of hepatitis B virus: Complete genome and phylogenetic relatedness
18. Molecular epidemiology of hepatitis B viral serotypes and genotypes in Taiwan
19. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B
20. Natural history of chronic hepatitis B virus infection in adults with emphasis on the occurrence of cirrhosis and hepatocellular carcinoma
21. Chronic hepatitis B
22. Acute exacerbation in chronic type B hepatitis: Comparison between HBeAg and antibody-positive patients
23. Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology
24. Acute flares in chronic hepatitis B: The natural and unnatural history of an immunologically mediated liver disease
25. Hepatitis B virus mutants
26. Hepatitis B e antigen-negative chronic hepatitis B
27. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants
28. Persistent hepatitis B virus: Clinically significant or purely occult?
29. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease
30. Cytotoxic T cells and viral hepatitis
31. Noncytolytic control of viral infections by the innate and adaptive immune response
32. Alteration of the dismal natural history of fibrosing cholestatic hepatitis secondary to hepatitis B virus with the use of lamivudine
33. Hepatitis B virus genotype distribution among chronic hepatitis B virus carriers in Shanghai, China
34. Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan
35. Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent
36. Acute exacerbations of chronic hepatitis B are rarely associated with superinfection of hepatitis B virus
37. Hepatitis B genotypes and the response to interferon therapy
38. Molecular characteristics of hepatitis B virus genotype A confer a higher response rate to interferon treatment
39. Hepatitis B viral genotypes and lamivudine resistance
40. 20-Fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw
41. Genotype may correlate with liver carcinogenesis and tumor characteristics in cirrhotic patients infected with hepatitis B virus subtype adw
42. Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers
43. Clinical and virological aspects of hepatitis B genotypes B and C-infected blood donors
44. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C
45. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: Correlation with viral persistence and disease severity
46. Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection
47. Clinical relevance of hepatitis B viral genotypes: A case of deja vu?
48. Naturally occurring variants of hepatitis B virus
49. Clinical relevance of hepatitis B viral mutations
50. Public health measures to control hepatitis B virus infection in the developing countries of the Asia-Pacific region
51. Hepatitis B third-generation vaccines: Improved response and conventional vaccine non-response-evidence for genetic basis in humans
52. Immune response to the pre-S(1) region of hepatitis B surface antigen (HBsAg): A pre-S(1)-specific T cell response can bypass nonresponsiveness to the pre-S(2) and S regions of the HBsAg
53. Adult hepatitis B vaccination using a novel triple antigen recombinant vaccine
54. Hepatitis B virus infection and chronic liver diseases in Taiwan
55. Hepatitis B virus, the major etiology of hepatocellular carcinoma
56. Vertical transmission of hepatitis B antigen in Taiwan
57. A mass vaccination programme in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen carrier mothers
58. Seroepidemiologic survey for hepatitis B virus infection in Taiwan: The effect of hepatitis B mass immunisation
59. Nationwide vaccination: A success story in Taiwan
60. Efficacy of a mass hepatitis B vaccination programme in Taiwan
61. Hepatitis B Virus Infection in Children and Adolescents in a Hyperendemic Area: 15 Years after Mass Hepatitis B Vaccination
62. Seroepidemiology of hepatitis B virus infection in children - Ten years of mass vaccination in Taiwan
63. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children
64. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls
65. Recent updates in hepatitis vaccination and the prevention of hepatocellular carcinoma
66. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan
67. A mathematical model of hepatitis B virus transmission and its application for vaccination strategy in China
68. Rationale for the infant and adolescent vaccination programmemes in Italy
69. Elimination of new chronic hepatitis B virus infections: Results of the Alaska immunisation programme
70. Hepatitis B vaccination in infancy in The Gambia: Protection against carriage at 9 years of age
71. Impact of hepatitis B immunisation as part of the EPI
72. Seroepidemiology of hepatitis B virus infection in Saudi children 8 years after a mass hepatitis B vaccination programme
73. Effect of hepatitis B vaccination programme on the prevalence of hepatitis B virus infection
74. Prevention and control of hepatitis B virus infection in Singapore
75. Toward the global elimination of hepatitis B virus transmission
76. Granulocyte-macrophage colony-stimulating factor enhances the efficacy of hepatitis B virus vaccine in previously unvaccinated haemodialysis patients
77. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen
78. Evaluation of a new hepatitis B triple-antigen vaccine in inadequate responders to current vaccines
79. Effect of hepatitis B virus mutants on efficacy of vaccination
80. The clinical significance of surface antigen variants of hepatitis B virus
81. Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan
82. Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus
83. Hepatitis B virus mutants and efficacy of vaccination
84. Vaccinations and the risk of relapse in multiple sclerosis
85. Hepatitis B vaccination and the risk of multiple sclerosis
86. School-based hepatitis B vaccination programmeme and adolescent multiple sclerosis
87. No increase in demyelinating diseases after hepatitis B vaccination
88. Hepatitis B vaccine and central nervous system demyelinating diseases. Viral Hepatitis Prevention Board
89. Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine
90. Hepatitis B vaccination in high-risk infants: 10-Year follow-up
91. Are booster immunisations needed for lifelong hepatitis B immunity?
92. The hepatitis B prevention education programmeme in Poland
93. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant
94. Lamivudine in the last 4 weeks of pregnancy to prevent perinatal transmission in highly viremic chronic hepatitis B patients
95. Hepatitis B surface antigenemia at birth: A long-term follow-up study
96. DNA-mediated immunisation of mice with plasmid encoding HBs antigen
97. Strategies to prevent and control hepatitis B and C virus infections: A global perspective
98. Hepatitis B infection: Pathogenesis and management